How to Get Tresiba (Insulin Degludec) in Texas

What Is Tresiba and Why Does Access Matter in Texas?

Insulin degludec is an ultra-long-acting basal insulin with a half-life exceeding 25 hours, giving it the flattest pharmacokinetic profile of any commercially available basal insulin [1]. The FDA approved Tresiba in 2015 for glycemic control in adults and children (age 1 year and older) with type 1 or type 2 diabetes.

Texas has roughly 2.7 million adults diagnosed with diabetes, according to the CDC's National Diabetes Statistics Report. Access to newer basal insulins like degludec is shaped by prescriber availability, insurance formulary placement, and state-level telehealth regulations. Each of these factors functions differently in Texas than in states with broader Medicaid formularies or more restrictive telehealth statutes.

The DEVOTE trial (N=7,637) demonstrated that insulin degludec was non-inferior to insulin glargine U100 for major adverse cardiovascular events (HR 0.91, 95% CI 0.78 to 1.06) while producing 40% fewer episodes of severe hypoglycemia during the maintenance period [1]. That hypoglycemia reduction is clinically meaningful for patients whose work schedules, rural locations, or limited monitoring access make tight glucose control dangerous.

Who Can Prescribe Tresiba in Texas?

Any Texas-licensed physician (MD or DO), nurse practitioner with prescriptive authority, or physician assistant practicing under a supervising physician can prescribe Tresiba. Texas does not restrict insulin prescribing to endocrinologists. Primary care providers write the majority of basal insulin prescriptions statewide.

NPs in Texas gained independent prescriptive authority for non-controlled substances, including insulin, under revisions to the Texas Occupations Code that took effect in recent legislative sessions. PAs must still maintain a prescriptive authority agreement with a supervising physician, but the agreement can be broad enough to cover chronic disease management including diabetes.

Endocrinologist density matters for complex cases. Texas has approximately 1.2 endocrinologists per 100,000 residents, well below the national average [2]. In rural counties west of I-35, a patient may face a 90-minute drive to the nearest specialist. This gap is exactly where telehealth fills a measurable clinical need.

How Telehealth Prescribing Works for Tresiba in Texas

Texas law permits prescribers to initiate and manage insulin therapy via synchronous audio-video telehealth visits. No prior in-person visit is required for non-controlled medications like insulin degludec.

A telehealth visit for Tresiba typically follows this workflow. The patient schedules a consultation with a licensed Texas prescriber or a prescriber licensed in Texas through an interstate compact. During the visit, the clinician reviews the patient's HbA1c, fasting glucose, renal function (eGFR), hepatic panel, and any prior insulin regimen. If degludec is appropriate, the prescriber sends an electronic prescription to the patient's chosen pharmacy. Most pharmacies in Texas accept e-prescriptions for non-controlled medications without any additional verification beyond standard DEA and state board requirements.

Texas does not require a separate telehealth consent form for non-controlled prescription medications, though most platforms include one as a matter of best practice. The Texas Medical Board has clarified that the standard of care for a telehealth visit is identical to an in-person visit. A prescriber who initiates insulin remotely must still arrange appropriate follow-up, including titration guidance and hypoglycemia education.

Typical turnaround from telehealth consultation to pharmacy pickup is 1 to 3 business days, assuming no prior authorization delay. If the insurer requires prior authorization, add 1 to 5 business days depending on the plan.

Labs Required Before Starting Tresiba in Texas

Prescribers in Texas follow the same evidence-based lab requirements as those in any other state. No Texas-specific lab mandates exist for insulin prescribing, but insurers may require documented lab values for prior authorization approval.

The American Diabetes Association Standards of Care recommend the following baseline labs before initiating or changing basal insulin therapy:

• HbA1c: confirms the degree of glycemic burden. Most prior authorization forms require an HbA1c value dated within 90 days.
• Fasting plasma glucose: provides a point-in-time snapshot. Useful for initial dose calibration.
• Basic metabolic panel (BMP): includes serum creatinine and calculated eGFR. Insulin degludec does not require dose adjustment for renal impairment, but kidney function informs overall diabetes management [3].
• Hepatic function panel: AST and ALT. Insulin clearance is partly hepatic, and liver disease can alter insulin sensitivity.
• C-peptide (type 1 diabetes or diagnostic uncertainty): helps differentiate type 1 from type 2 and guides whether basal-only therapy is sufficient.
• Lipid panel: not required for the insulin prescription itself but recommended at baseline per ADA guidelines for comprehensive cardiometabolic risk assessment.

A prescriber may start Tresiba without waiting for every lab result if the patient has a documented prior diagnosis and recent labs on file. Telehealth platforms that prescribe insulin typically request that patients upload lab results drawn within the preceding 90 days.

Insurance Coverage and Prior Authorization in Texas

Most commercial insurers in Texas cover Tresiba on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formularies. Step therapy requirements are common. Insurers frequently require documented failure of, or intolerance to, insulin glargine U100 (Lantus or biosimilars) before approving degludec.

Texas Medicaid does not cover Tresiba for type 2 diabetes. Patients on Texas Medicaid with type 2 diabetes are typically directed to insulin glargine or NPH insulin. For type 1 diabetes, Medicaid coverage varies by managed care organization (MCO), and some MCOs have approved degludec on a case-by-case basis with clinical justification documenting recurrent severe hypoglycemia on glargine.

What Prior Authorization Documentation Requires

A standard prior authorization request for Tresiba in Texas includes:

1. Diagnosis code (ICD-10): E11.65 for type 2 with hyperglycemia, E10.65 for type 1.
2. Current HbA1c dated within 90 days.
3. Documentation of step therapy: records showing the patient used insulin glargine U100 for at least 90 days (some plans require 180 days) and either failed to reach target HbA1c or experienced recurrent hypoglycemia.
4. Prescriber's letter of medical necessity: a brief clinical note explaining why degludec is preferred. Citing the DEVOTE trial's 40% reduction in severe hypoglycemia [1] strengthens the argument.
5. Patient consent: some plans require a signed acknowledgment that the patient understands the drug's cost-sharing tier.

Turnaround on prior authorization decisions is governed by Texas Insurance Code Chapter 4201, which requires insurers to issue a determination within 3 business days for non-urgent requests. Urgent requests (e.g., a patient being discharged from the hospital on degludec) must receive a response within 24 hours. Denials can be appealed through the insurer's internal process and then to the Texas Department of Insurance.

Novo Nordisk Patient Assistance and Cost-Reduction Programs

Tresiba's wholesale acquisition cost exceeds $400 per FlexTouch pen for a 30-day supply. Patients without coverage or with high cost-sharing have several options.

Novo Nordisk's patient assistance program (PAP) provides Tresiba at no cost to qualifying uninsured patients with household income at or below 400% of the federal poverty level. The application requires proof of income, a valid prescription, and a signed prescriber attestation. Processing takes 4 to 6 weeks.

The Novo Nordisk copay savings card reduces out-of-pocket cost to as low as $25 per 30-day supply for commercially insured patients. The card does not apply to government insurance (Medicare Part D, Medicaid, TRICARE). Patients in Texas using this card at major retail chains (CVS, Walgreens, H-E-B Pharmacy) report consistent acceptance.

Dr. Ildiko Lingvay, Professor of Internal Medicine at UT Southwestern Medical Center, has noted: "Cost remains the single largest barrier to optimal basal insulin therapy in Texas. When a patient tells me they are rationing insulin, I immediately switch the conversation to assistance programs before discussing dose adjustments."

Pharmacy Access Across Texas

Tresiba is stocked at all major retail pharmacy chains operating in Texas, including CVS, Walgreens, Walmart, H-E-B Pharmacy, and Kroger Pharmacy. Specialty pharmacy dispensing is not required because degludec is a retail-distributed product.

Mail-order pharmacy is a practical option for patients in rural West Texas, the Panhandle, and the Rio Grande Valley. Express Scripts, OptumRx, and CVS Caremark all include Tresiba on their mail-order formularies (subject to the patient's plan formulary). A 90-day mail-order supply typically reduces per-unit cost by 10% to 20% compared to 30-day retail fills.

503A Compounding Pharmacies in Texas

Texas-licensed 503A compounding pharmacies may compound insulin degludec pursuant to a patient-specific prescription. The Texas State Board of Pharmacy regulates these pharmacies under the Texas Pharmacy Act and requires compliance with USP <797> sterile compounding standards. A 503A pharmacy cannot compound a copy of a commercially available drug (like Tresiba) unless the prescriber documents a clinical difference, such as an allergy to an inactive ingredient in the commercial formulation or a need for a concentration not commercially available.

In practice, 503A compounding of insulin degludec in Texas is rare. Most patients and prescribers use the commercial Tresiba FlexTouch pen. Patients who believe they need a compounded formulation should confirm with the compounding pharmacy that it holds a current Texas sterile compounding license and that the prescriber has documented the clinical justification.

Transferring a Tresiba Prescription to Texas

Patients moving to Texas from another state can transfer a valid Tresiba prescription to a Texas pharmacy. Texas Board of Pharmacy rules allow prescription transfers for non-controlled medications between any two pharmacies, including across state lines.

The process is straightforward. The patient contacts the receiving Texas pharmacy and provides the name and phone number of the originating pharmacy. The receiving pharmacist contacts the originating pharmacy, verifies the prescription, and processes the transfer. Electronic transfers via the Surescripts network are also accepted. No prescriber involvement is needed for the transfer itself, though the patient will eventually need to establish care with a Texas-licensed provider for refills.

One caveat: prior authorization does not transfer between insurers. If the patient's insurance plan changes due to the move, a new prior authorization may be required under the new plan's formulary rules.

Dosing and Titration After Access

Once the patient has Tresiba in hand, the standard starting dose for insulin-naive patients with type 2 diabetes is 10 units once daily, titrated by 2 units every 3 to 4 days to a fasting plasma glucose target of 80 to 130 mg/dL [3]. For patients with type 1 diabetes, degludec replaces the existing basal insulin at a 1:1 unit conversion from glargine U100, with subsequent titration based on fasting glucose.

Degludec's ultra-long duration of action (exceeding 42 hours at steady state) means that dose adjustments take 3 to 4 days to reach full effect. Prescribers should counsel patients against making daily dose changes based on single fasting glucose readings. The ADA Standards of Care recommend using 3-day fasting glucose averages for titration decisions.

A key clinical advantage confirmed by DEVOTE: the flexibility of injection timing. Patients who occasionally vary their injection time by up to 8 hours showed no significant increase in hypoglycemia risk compared to fixed-time dosing [1]. This flexibility is particularly relevant for Texas shift workers in industries like oil and gas, healthcare, and agriculture.

Comparing Degludec to Other Basal Insulins Available in Texas

Texas patients and prescribers choosing between basal insulins should weigh three factors: hypoglycemia risk, dosing flexibility, and formulary cost.

The DEVOTE trial established degludec's cardiovascular safety and hypoglycemia advantage over glargine U100 [1]. The SWITCH 1 (type 1, N=501) and SWITCH 2 (type 2, N=721) trials, both double-blind crossover designs, confirmed significantly lower rates of overall symptomatic hypoglycemia with degludec versus glargine U100 (rate ratio 0.89 in SWITCH 2, P=0.036) [4].

Glargine U300 (Toujeo) also offers reduced hypoglycemia versus glargine U100, but no head-to-head trial has directly compared degludec to glargine U300 with hypoglycemia as the primary endpoint. The CONCLUDE trial attempted this comparison but was confounded by a protocol-mandated titration switch mid-study [5].

For Texas Medicaid patients who cannot access Tresiba, glargine U100 biosimilars (Semglee, Rezvoglar) remain the most accessible long-acting option. NPH insulin is available without prior authorization on virtually all Texas Medicaid MCO formularies but carries a substantially higher hypoglycemia risk. The Endocrine Society guidelines recommend against NPH as first-line basal insulin when long-acting analogs are accessible [6].

Patients with commercial insurance in Texas who face high degludec copays should ask their prescriber about insulin glargine biosimilars as a clinically reasonable alternative, reserving degludec for cases where hypoglycemia risk or dosing flexibility is the primary clinical concern.

The recommended starting dose for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily, titrated upward by 2 units every 3 days until fasting glucose consistently falls between 80 and 130 mg/dL.